找回密碼
 To register

QQ登錄

只需一步，快速開(kāi)始

掃一掃，訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T

[復(fù)制鏈接]
查看: 18223|回復(fù): 54
樓主
發(fā)表于 2025-3-21 16:11:48 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
期刊全稱Biosimilars for Cancer Treatment
期刊簡(jiǎn)稱A Promising Approach
影響因子2023Shvetank Bhatt,Harish Dureja,Kamal Dua
視頻videohttp://file.papertrans.cn/193/192718/192718.mp4
發(fā)行地址Covers the recent clinical trials of biosimilars for cancer treatment.Provides information about the analysis of regulatory complexities in cancer care.Explores the role of biosimilars in improving th
圖書(shū)封面Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T
影響因子.The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers...It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment..
Pindex Book 2024
The information of publication is updating

書(shū)目名稱Biosimilars for Cancer Treatment影響因子(影響力)




書(shū)目名稱Biosimilars for Cancer Treatment影響因子(影響力)學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment被引頻次




書(shū)目名稱Biosimilars for Cancer Treatment被引頻次學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment年度引用




書(shū)目名稱Biosimilars for Cancer Treatment年度引用學(xué)科排名




書(shū)目名稱Biosimilars for Cancer Treatment讀者反饋




書(shū)目名稱Biosimilars for Cancer Treatment讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:48:20 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:51:31 | 只看該作者
地板
發(fā)表于 2025-3-22 07:58:13 | 只看該作者
5#
發(fā)表于 2025-3-22 10:20:44 | 只看該作者
6#
發(fā)表于 2025-3-22 15:49:15 | 只看該作者
7#
發(fā)表于 2025-3-22 19:01:48 | 只看該作者
8#
發(fā)表于 2025-3-23 00:21:12 | 只看該作者
U. M. Lütolf,P. Huguenin,C. Glanzmann for use in both the disease itself and as supportive drugs for cancer patients. The reduction in the treatment cost using trastuzumab biosimilars is approximately 20–30% lower in comparison to the costs using the reference product. The supportive drugs include haematopoietic growth factors like ery
9#
發(fā)表于 2025-3-23 01:35:18 | 只看該作者
10#
發(fā)表于 2025-3-23 09:02:06 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 16:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
拜泉县| 即墨市| 长白| 永春县| 镶黄旗| 屏山县| 沙洋县| 增城市| 布拖县| 台北县| 金山区| 綦江县| 香河县| 霍林郭勒市| 新平| 腾冲县| 保康县| 丹棱县| 绍兴市| 婺源县| 土默特右旗| 福鼎市| 塘沽区| 本溪市| 巫山县| 公主岭市| 乳山市| 九江县| 海安县| 花垣县| 长汀县| 大竹县| 体育| 昌图县| 通州区| 新丰县| 柞水县| 东明县| 新兴县| 三穗县| 嫩江县|